34 results about "Japanese encephalitis vaccine" patented technology

The invention discloses a treatment liquid for desorbing antigens in an aluminum salt adsorption type vaccine. The treatment liquid is a phosphate buffer solution or a citrate buffer solution, wherein the buffer solution contains proteins and at least one acid and/or salts of the acids. The invention further discloses a method using the provided treatment liquid to measure the antigen content of an aluminum salt adsorption type vaccine. The provided method reduces the interference brought by the aluminum adjuvant in Japanese encephalitis vaccine, is capable of rapidly and precisely measuring the antigen content in an adsorption type Japanese encephalitis inactivated vaccine, has the characteristics of good durability, high accuracy, and high precision, and can provide references for quality control of aluminum adjuvant adsorption type Japanese encephalitis inactivated vaccines.

The invention discloses a Japanese encephalitis vaccine prepared by human embryonic lung fibroblasts and a preparation method thereof, comprising culture and expansion of the human embryonic lung fibroblasts. The method comprises the following steps: Japanese encephalitis virus strain P3, strain SA14-14-2 or strain Nakayama is naturalized and inoculated to fit the human embryonic lung fibroblasts, and the seeds of Japanese encephalitis viruses are prepared on the human embryonic lung fibroblasts; wherein, an inactivated Japanese encephalitis vaccine also comprises the steps of harvesting viruses, inactivating viruses, concentrating, purifying and the like; an attenuated live vaccine also comprises the steps of harvesting viruses, concentrating, purifying and the like. Due to being prepared by healthy human embryonic lung fibroblasts, the two kinds of Japanese encephalitis vaccines do not contain any adventitious pollution agent and tumorigenicity, has high purity after being purified and has the advantages of good immune effect and high security. The preparation method of the invention is suitable for large-scale industrial production and can meet the preparation processes of Japanese encephalitis vaccines required by domestic and abroad markets.

The invention relates to a preparation method for diploid cell Japanese encephalitis vaccine and purified encephalitis vaccine. The method uses a serum-free medium to culture human diploid cell Japanese encephalitis purified vaccine, thus greatly reducing anaphylactic reaction and being beneficial to purification.

The present inventors improved methods for inactivating Japanese encephalitis virus vaccines, and assessed the safety of vaccines produced by combining multiple vaccines. The present inventors successfully produced safer Japanese encephalitis vaccines by cell culture, which can be stored more stably over a long period than conventional Japanese encephalitis vaccines. Furthermore, it is also expected that the production methods can be used to produce other viral vaccines with excellent storage stability.

The invention provides a method for preparing the positive serum of an antibody against the porcine Japanese encephalitis virus. The method comprises the following steps: vaccine preparation; negative pig screening; immunization; and harvesting and identification of the positive serum. According to the method, a negative pig is basically immunized with a live porcine Japanese encephalitis vaccine (strain SA14-14-2); and then a high-titer inactivated porcine Japanese encephalitis vaccine (strain SA14-14-2) prepared by using concentration and purification technology is used for supplementary immunization so as to prepare the positive serum of the antibody against the porcine Japanese encephalitis virus. The positive serum of the antibody against the porcine Japanese encephalitis virus prepared in the invention avoids the risk of usage of virulent vaccines and has the advantages of high safety compared with preparation of positive serum from virulent Japanese encephalitis vaccines; and compared with serum prepared from mice, the positive serum prepared from the pig has the advantages of a larger harvesting amount of serum, lower cost and prominent large-scale application prospects.

The invention provides a vaccine protection agent which is characterized by comprising the following components by weight: 60 to 200 parts of disaccharides, 3 to 10 parts of gelatin, 0.5 to 10 parts of amino acid, 3 to 10 parts of urea, 3 to 10 parts of sorbitol and 2 to 10 parts of human albumin. The invention also provides a combined measles and Japanese encephalitis vaccine and a preparation method thereof. The vaccine protection agent provided in the invention can effectively enhance stability of the combined measles and Japanese encephalitis vaccine and has a high application value.

The invention belongs to the field of biological products, in particular to a new application of the existing product-rabies human immunoglobulin. The technical proposal of the invention is the new application of rabies human immunoglobulin in preparing medicine for preventing and controlling Japanese encephalitis. The invention also provides a combined vaccine for rabies and Japanese encephalitis. The vaccine of the invention has better effect than conventional Japanese encephalitis vaccine in preventing and controlling Japanese encephalitis and fundamental immunity for resisting the rabies virus is obtained. The combined vaccine features scientific immunization schedule, few times of vaccine inoculation, easy promotion of inoculation and good effect in boostering immunization in case of emergency in preventing and controlling the rabies. The antibody and the vaccine jointly solve the technical and application problems of preventing and controlling the Japanese encephalitis and the rabies, thus enjoying great social and economic significance.

The invention provides a method for preparing inactivated Japanese encephalitis vaccine by a bioreactor. The method includes by the aid of the bioreactor and a Cytodex-1 microcarrier system, subjecting high-density Vero cells adaptive to Japanese encephalitis virus P3-strain to virus infection by utilizing the P3-strain Japanese encephalitis virus with good antigenicity; according to multiplication conditions of the Japanese encephalitis virus P3-strain on the Vero cells, harvesting virus liquid after the cytopathic effect reaches a certain degree so as to increase virus titer from 105-6PFU/ml to 107-8PUF/ml at least and increase virus content by 10 times at least; and inactivating harvest virus liquid, adding additives, and then packing to obtain high-quality vaccine products. The prepared vaccine is safe and effective, production process is stable, and production quality is controllable.

The invention provides a JE (Japanese encephalitis) vaccine soluble microneedle patch, which comprises a needle body and a backing. The needle body is composed of a JE vaccine, a matrix material and an adjuvant, wherein the adjuvant is a mixture of MDP and GM-CSF; and the content ratio of the adjuvant to the Japanese encephalitis vaccine is (1: 1) to (1: 3). The JE vaccine soluble microneedle prepared in the invention has good immune effect and high mechanical strength of the needle body, and is expected to replace a JE vaccine injection and realize painless minimally invasive administration.

The invention provides a method for proliferation of a Japanese encephalitis virus. The method for proliferation of the Japanese encephalitis virus comprises the steps of culturing cells, inoculating Japanese encephalitis viruses to the cells which are provided with mono-layers in an overgrowing mode, and directly obtaining a virus solution until a rate of a cytopathic effect reaches to 75%-95% after inoculation. The invention further provides a preparation method of Japanese encephalitis vaccines. The method for proliferation of the Japanese encephalitis virus and the preparation method of the Japanese encephalitis vaccines can remarkably improve a Japanese encephalitis virus titer, and meanwhile shorten production periods, and can prepare the Japanese encephalitis vaccines which are better, stable, and good in immunogenicity.

The invention discloses a large-scale culture method of porcine Japanese encephalitis vaccine antigens. According to the large-scale culture process of the porcine Japanese encephalitis vaccine antigens, porcine kidney cells PK-15 are used for culturing porcine Japanese encephalitis virus, multiple batches of virus can be continuously harvested through one-time virus inoculation, and the titer ofthe virus is equivalent to that of BHK-21 and VERO cells or higher than an existing culture process, the yield of the virus is greatly increased, the production cost is reduced, and the method is a porcine Japanese encephalitis vaccine antigen culture process suitable for large-scale production.

The invention provides an ABCYW135 group meningococcus/Japanese encephalitis combined vaccine, which is prepared by the following steps: respectively extracting capsular polysaccharides from A group meningococcus, C group meningococcus, W135 group meningococcus and Y group meningococcus, purifying, and combining the activated capsular polysaccharides with diphtheria CRM197 protein; using PorA protein on outer membrane vesicles of group B meningococcus; using Vero cells for culturing encephalitis B viruses, after inactivation and purification, mixing the components according to a certain proportion, and the mixture is used for preventing infection caused by ABCYW135 group meningococci and Japanese encephalitis viruses.

The invention relates to a gelatin-free freeze-drying stabilizer used for a human Japanese encephalitis vaccine. The freeze-drying stabilizer is free of gelatin; and according to test and detection results, the prepared vaccine has high stability and security and small irritation and is free of known allergic population. A formula for the freeze-drying stabilizer comprises 0.02 to 0.05 M of disodium hydrogen phosphate (including aquo-compounds thereof), 0.08 to 0.15 M of cane sugar, 0.02 to 0.06 M of sodium dihydrogen phosphate (including aquo-compounds thereof), 0.50 to 0.80 M of urea and 0.20 to 0.70 M of lactose, and the pH value of the freeze-drying stabilizer is 6.5 to 7.8.